Relevance of positron emission tomography (PET) in oncology

Strahlentherapie und Onkologie

Volumn 175, Issue 8, 1999, Pages 356-373

  Weber, Wolfgang A ^a   Avril, Norbert ^b   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Fluorodeoxyglucose; Nuclear medicine; Positron emission tomography; Tumor diagnosis

Indexed keywords

CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT; THYMIDINE;

BILIARY TRACT CANCER; BONE CANCER; BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; HEAD AND NECK CANCER; HUMAN; ISOTOPE LABELING; LUNG CANCER; LYMPHOMA; MELANOMA; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; UROGENITAL TRACT CANCER;

CARBON RADIOISOTOPES; FLUORIDES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; METHIONINE; MISONIDAZOLE; NEOPLASM STAGING; NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYMIDINE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032775641     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000660050022     Document Type: Review

References (168)

1. Aassar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999;210:177-81.
2. Adams S, Baum R, Rink T, Schumm Drager PM, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.
3. Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-60.
4. Adler LP, Faulhaber PF, Schnur KC, et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997;203:323-7.
5. Ahlstrom H, Eriksson B, Bergstrom M, et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333-7.
6. Ahlstrom H, Malmstrom PU, Letocha H, et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996;37:180-5.
7. Altenvoerde G, Lerch H, Kuwert T, et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998;383:160-3.
8. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200:135-41.
9. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-57.
10. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204-9.
11. Bailet JW, Sercarz JA, Abemayor E, et al. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 1995;105:135-9.
12. Bares R, Dohmen BM, Cremerius U, et al. Ergebnisse der Positronenemissionstomographie mit Fluor-18-markierter Fluordesoxyglukose bei Differentialdiagnose und Staging des Pankreaskarzinoms. Radiologe 1996;36:435-40.
13. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79-86.
14. Barker FG, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26.
15. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-70.
16. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol (Stockh) 1996;116:332-5.
17. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987;235:1495-8.
18. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4.
19. Braams JW, Pruim J, Freling NJ, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211-6.
20. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9: 410-4.
21. Bury T, Dowlati A, Paulus P, et al. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 1996;23:204-6.
22. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560-4.
23. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-methionine. J Neurooncol 1986;3:397-404.
24. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91: 3340-6.
25. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331-8.
26. Chin R Jr, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090-6.
27. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9.
28. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998;39: 815-22.
29. Cremerius U, Fabry U, Kröll U, et al. Klinische Wertigkeit der FDG-PET zur Therapiekontrolle be malignen Lymphomen - Ergebnisse einer retrospektiven Studie an 72 Patienten. Nuklearmedizin 1999;38:24-30.
30. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4-8.
31. Crippa F, Seregni E, Agresti R, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-34.
32. Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
33. De Witte O, Levivier M, Violon P, et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470-6; discussion 476-7.
34. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-74.
35. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-5; discussion 515-6.
36. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52.
37. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
38. Derlon JM, Bourdet C, Bustany P, et al. [11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720-8.
39. Derlon JM, Petit Taboue MC, Chapon F, et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 1997;40:276-87; discussion 287-8.
40. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology (NY) 1982;32:1323-9.
41. Diederichs CG, Staib L, Glatting G, Neurology FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030-3.
42. Dose J, Avril N, Ziegler S, et al. Stellenwert der Positronenemissionstomographie (PET) mit F-18-Fluordeoxyglukose in der Diagnostik von Mammatumoren. Geburtshilfe Frauenheilkd 1997;57:315-20.
43. Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol 1998;170: 1369-73.
44. Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography [see comments]. Am J Roentgenol 1997;168:1357-60.
45. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
46. Fischbein NJ, OS AA, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck [see comments]. Am J Neuroradiol 1998;19:1189-96.
47. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-23.
48. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
49. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771-7.
50. Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428-36.
51. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
52. Gasparoni P, Rubello D, Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997;20:527-30.
53. Greven KM, Williams DW, Keyes JW Jr, et al. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? Cancer J Sci Am 1997;3:353-7.
54. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-95.
55. Grunwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131-iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
56. Guhlmann A, Storck M, Kotzerke J, et al. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Thorax 1997;52:438-41.
57. Guhlmann C, Reske S. PET in der Onkologie - klinische Indikationen: Ergebnisse der 2. deutschen Konsensuskonferenz. Forum DKG 1999;14: 32-45.
58. Gupta N, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943-8.
59. Harney JV, Wahl RL, Liebert M, et al. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991;145:279-83.
60. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology (NY) 1998;50:1316-22.
61. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993;79:853-8.
62. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy [see comments]. J Nucl Med 1993;34:773-9.
63. Higashi K, Seki H, Taniguchi M, et al. Bronchioloalveolar carcinoma: false-negative reuslts on FDG-PET. J Nucl Med 1997;38:79P.
64. Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-9: discussion 769-71.
65. Hsueh EC, Gupta RK, Glass EC, et al. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 1998;187:191-7.
66. Hubner KF, McDonald TW, Niethammer JG, et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993; 51: 197-204.
67. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345-52.
68. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-93.
69. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998;39:663-7.
70. Ito K, Kato T, Ohta T, et al. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 1996;23:1372-7.
71. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175-81.
72. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85.
73. Kalo T, Fukatsu H, Ito K, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995;22:32-9.
74. Keiding S, Hansen SB, Rasmussen HH, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28:700-6.
75. Keogan MT, Lowe VJ, Baker ME, et al. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997;22:332-7.
76. Keogan MT, Tyler D, Clark L, et al Diagnosis of pancreatic carcinoma: role of FDG PET. Am J Roentgenol 1998;171:1565-70.
77. Kole AC, Nieweg OE, Hoekstra HJ, et al. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998;39:810-5.
78. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-6.
79. Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521-7.
80. Kosuda S, Kison PV, Greenough R, et al. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997;24:615-20.
81. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998;339:941-6.
82. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
83. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131: 703-7.
84. Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995;197:205-11.
85. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522-7.
86. Laubenbacher C, Saumweber D, Wagner Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-57.
87. Leskinen Kallio S, Nagren K, Lehikoinen P, et al. Uptake of HC-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991;64:1121-4.
88. Leskinen Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991;32:1211-8.
89. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-6.
90. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-9.
91. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16 1075-84.
92. Lowe VJ, Huffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-6.
93. Lowe VJ, Naunheim KS. Positron emission tomography in lung cancer. Ann Thorac Surg 1998;65:1821-9.
94. Lucas JD, MJ OD, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg [Br] 1998;80:441-7.
95. Macfarlane DJ, Sondak V, Johnson T, et al. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-6.
96. Mathias CJ, Welch MJ, Kilbourn MR, et al. Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. Life Sci 1987;41:199-206.
97. McGuirt WF, Williams DW, Keyes JW Jr, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995;105:373-5.
98. McLoud T, Bourgouin P, Grenberg R, et al. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23.
99. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, et al. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998;83:245-53.
100. Monakhov N, Neistadt E, Shavlovskii M, et al. Physicochemical properties and isoenzymes of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978;61:27-33.
101. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
102. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-9.
103. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-5.
104. Musholt TJ, Musholt PB, Dehdashti F, et al. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997;122: 1049-60; discussion 1060-1.
105. Myers LL, Wax MK, Nabi H, et al. Positron emission tomography in the evaluation of the NO neck. Laryngoscope 1998;108:232-6.
106. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-6.
107. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-61.
108. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997;33:1234-41.
109. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography [see comments]. Ann Surg Oncol 1997;4:613-20.
110. Orlefors H, Sundin A, Ahlstrom H, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 1998;16:2534-41.
111. Palmedo H, Bender H, Grunwald F, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997;24:1138-45.
112. Pasquali C, Rubello D, Sperti C, et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998;22:588-92.
113. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-82.
114. Paulus P, Sambon A, Vivegnis D, et al. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998;108: 1578-83.
115. Präuer H, Weber W, Römer W, et al. Evaluation of pulmonary nodules by positron emission tomography using the glucose analogue fluorine-18-fluorodeoxyglucose (FDG). A controlled prospective study in 50 patients. Br J Surg 1998;85:1506-11.
116. Rahn AN, Baum RP, Adamietz IA, et al. Stellenwert der 18F-Fluordeoxyglucose-Positronenemissionstomographie in der Radiotherapieplanung von Kopf-Hals-Tumoren. Strahlenther Onkol 1998;174:358-64.
117. Rankin SC, Taylor H, Cook GJ, et al. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998;53:659-65.
118. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
119. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047-58.
120. Rege SD, Chaiken L, Hoh CK, et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993;189:807-12.
121. Rigo P, Paulus P, Kaschten B, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641.
122. Rinne D, Baum RP, Hor G, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-71.
123. Romer W, Avril N, Dose J, et al. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 1997;166:62-8.
124. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
125. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741-7.
126. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.
127. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618-23.
128. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
129. Schirrmeister H, Kotzerke J, Rentschler M, et al. Die Positronenemissionstomographie des Skelettsystems mit 18FNa: Häufigkeit, Befundmuster und Verteilung benigner Veränderungen. Fortschr Geh Rontgenstr Neuen Bildgeb Verfahr 1998;169:310-4.
130. Scott WJ, Gobar LS, Terry JD, et al. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-8.
131. Shawver LK, Olson SA, White MK, et al. Degradation and biosynthesis of the glucose transporter protein in chicken embryo fibroblasts transformed by the src oncogene. Mol Cell Biol 1987;7:2112-8.
132. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-6.
133. Shields AF, Lim K, Grierson J, et al. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990;31:337-42.
134. Shinoura N, Nishijima M, Hara T, et al. Brain tumors: detection with C-11 choline PET. Radiology 1997;202:497-503.
135. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998;25:259-64.
136. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
137. Shreve PD, Steventon RS, Deters EC, et al. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998;207:431-7.
138. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998;228: 220-7.
139. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-6.
140. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-9.
141. Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637-41.
142. Stollfuss JC, Glatting G, Friess H, et al. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation [see comments]. Radiology 1995;195:339-44.
143. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-32.
144. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173-80.
145. Tjuvajev JG, Avril N, Oku T, et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 1998;58:4333-41.
146. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-7.
147. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-9.
148. Torizuka T, Zasadny KR, Recker B, et al. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998;207:767-74.
149. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588-93.
150. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-81; discussion 1581-2.
151. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
152. Vansteenkiste JF, Stroohants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-9.
153. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6.
154. von Schulthess GK, Steinert HC, Dummer R, et al. Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. Acad Radiol 1998;5:Suppl 2:S300-2.
155. Wahl RL, Harney J, Hutchins G, et al. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 1991;146:1470-4.
156. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
157. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
158. Webb W, Gatsonis C, Zerhouni E, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the radiologie diagnostic oncology group. Radiology 1991;178:705-13.
159. Weber W, Bartenstein P, Groß M, et al. F-18-fluorodeoxyglucose PET and I-123-alpha-methyl-tyrosine SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802-8.
160. Weber W, Young C, Abdel-Dayem HM, et al. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999;40:574-8.
161. Weber W, Ziegler S, Thödtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using F-18-fluorodeoxyglucose and positron emission tomography (PET). J Nucl Med (in press).
162. Weber WA, Neverve J, Sklarek J, et al. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system. Eur J Nucl Med 1999;26:388-95.
163. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-92; discussion 892-3.
164. Wester H, Herz M, Weber W, et al. Synthesis, radiopharmacology and first human study of O2-F-18-fluorethyl-L-tyrosine (F-18-FET). J Nucl Med 1999;40:205-12.
165. Wilson CB, Young HE, Ott RJ, et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995;22:508-13.
166. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997;22:209-14.
167. Wurker M, Herholz K, Voges J, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583-6.
168. Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678-82.